S
ubsequent to hospitalization for an acute myocardial infarction (MI), patients remain at increased risk of death and recurrent cardiovascular events. Several biomarkers have emerged as potential tools for patient risk stratification and provide incremental information beyond established risk predictors. To date, such markers have largely been evaluated on an individual basis, and therefore limited data are available that compare the prognostic utility of multiple candidate markers simultaneously in the setting of an acute coronary syndrome.
Given that many markers reflect different pathobiological axes of response post-MI, a multimarker strategy might provide substantially more information for risk stratification than any individual marker on its own. 3 In addition, identifying such highrisk patients could aid in early triage decisions. In particular, past studies have demonstrated that there may be additive value for combining markers including those of myonecrosis, myocardial strain or stress, and vascular inflammation. [1] [2] [3] [4] [5] [6] [7] However, the identification of more recent candidate markers that reflect alternate pathways of disease or are more sensitive markers of underlying biology offer the possibility that a novel multimarker risk score may be able to provide incremental information for risk stratification. We therefore evaluated the prognostic utility of several established and novel candidate biomarkers in a trial population of patients with an acute MI and evaluated the role of a multimarker strategy in risk stratification across several pathobiological axes of myocardial injury, including inflammation, myocardial stress, structural changes, and myonecrosis.
Methods Study Population and Design
The design and results of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction 28 (CLARITY-TIMI 28) have previously been reported. 8, 9 In brief, CLARITY-TIMI 28 was a double-blind, randomized, multicenter clinical trial of clopidogrel versus placebo in addition to fibrinolytic therapy in 3491 patients with STEMI who presented within 12 hours of symptom onset. The choice of fibrinolytic and type of heparin were left at the discretion of the managing physician. Relevant exclusion criteria included age <18 or >75 years, use of clopidogrel in the 7 days preceding randomization, contraindications to fibrinolytic drugs, planned elective angiography within 48 hours, or evidence of cardiogenic shock. As part of the trial protocol, patients were scheduled to undergo coronary angiography 2 to 8 days after initiation of therapy to assess for late patency of the infarct-related artery. Angiography was permitted less than 48 hours only if clinically indicated. The decision for coronary revascularization was left to the discretion of the managing physician. Patients were followed for clinical outcomes, and adverse events through to 30 days after the time of randomization and vital status were obtained in 99.9% of all patients. The protocol was approved by the relevant institutional review boards, and written informed consent was obtained from all patients.
Outcomes
The prespecified clinical endpoint of interest for this analysis was the composite of cardiovascular death or heart failure (HF) based on previous prognostic assessments for the markers in acute coronary syndrome (ACS) patients. Other endpoints that were assessed in CLARITY-TIMI 28 were recurrent MI, recurrent ischemia requiring urgent revascularization, and TIMI flow grade 0 to 1 on protocol-mandated angiography. Endpoints were defined according to previously reported criteria. 8, 9 All ischemic events were adjudicated by a clinical events committee that was blinded to assigned treatment arm. Information on the development of new or worsening HF was collected from the case report forms.
Blood Sampling and Analysis
A sample of blood was obtained at time of enrollment and was available for testing in up to 1258 subjects who elected to participate and were at sites that participated in this optional substudy, which represented 36% of the overall study population of CLARITY-TIMI 28. Median time from symptom onset to randomization was 2.5 hours. There were no clinically meaningful differences in baseline characteristics of the biomarker group and the overall trial cohort. 10 The serum and plasma components were frozen and shipped to the TIMI Biomarker Core Laboratory (Boston, MA), where samples were stored at À70°C. 
Statistical Analysis
Continuous variables were compared using the Kruskal-Wallis test and categorical variables were compared using the v 2 test
for trend. The correlation between baseline biomarkers was assessed with Spearman's correlation coefficient. All biomarkers were first assessed by both categorizing the marker into quartiles and looking at the continuous association between biomarker and risk using logistic regression models (risk per SD of log-transformed biomarker). For troponin T, all patients who had undetectable levels were categorized as the referent group and patients with detectable levels were divided into tertiles in all models. After assessing the shape of the relationship with cardiovascular events, biomarkers were subsequently assessed as dichotomous variables before multimarker selection with the threshold applied at the concentration where an inflection in the risk of cardiovascular death or HF was most apparent. For most markers, this dichotomous threshold was applied at the fourth quartile (Q) with the first through third quartile as referent. The only exceptions were MPO, GDF-15, and PAPP-A where the threshold was applied between the first and second quartile (modeled as Q2-4:1). In the case of troponin T, 3 groups were used: undetectable, the first and second tertiles combined, and the third tertile. Logistic regression models were used to assess the relationship between marker and outcomes adjusting for age, sex, past HF, diabetes mellitus, past MI, systolic blood pressure, heart rate, Killip class II to IV, anterior ST-elevation MI (STEMI), creatinine clearance <60 mL/min, time to lytic, type of lytic, and randomized treatment arm. A multimarker strategy was assessed by introducing all markers at their dichotomous thresholds (except for troponin T, which was maintained as a 3-way variable) through a forward selection process with a P<0.05 for retention in the final model. Final candidate markers were subsequently confirmed through backward selection. Once the final model was determined, an integeric score system was created by summing the number of elevated markers. In the case of troponin T, 1 point was assigned to patients with a detectable troponin T concentration in the first or second tertile and 2 points were assigned to patients with a detectable troponin T concentration in the top tertile. The prognostic utility of the multimarker risk score and the TIMI Risk Score for STEMI 11 and GRACE Risk Score 12 were compared through assessment of the C-statistic, integrated discrimination index (IDI), and categoryless net reclassification index (NRI) that was calculated on a continuous basis, using previously described methodology. 13 A test for the equality of the area under the receiver-operating curves (AUCs) was applied using the algorithm described by DeLong et al. 14 Because all analyses were exploratory, tests were 2-sided with a P<0.05 considered to be significant.
Results
Baseline characteristics for the overall biomarker cohort and by quartile of biomarker are shown in Tables S1 through S12. Prognostic Utility of Individual Markers Table 2 shows the odds of cardiovascular death or HF per 1 SD increase in each biomarker as well as the incidence of cardiovascular death or HF through 30 days across quartiles GDF-15 indicates growth-differentiation factor-15; HF, heart failure; hsCRP, high-sensitivity C-reactive protein; MR-proADM, midregional proadrenomedullin; MR-proANP, midregional proatrial natriuretic peptide; NT-proBNP, NT-pro B-type natriuretic peptide; OR, odds ratio; PAPP-A, pregnancy-associated plasma protein A; ST2, suppression of tumorigenicity 2. *All patients with undetectable troponin T levels were grouped in quartile 1, and then patients with detectable troponin T levels were divided into tertiles. (Tables S13 and  S14 ). In general, biomarker concentration was not associated with the odds of MI, recurrent ischemia requiring urgent revascularization or TIMI flow grade 0 to 1, except for ST2, where higher levels of which were associated with recurrent MI and TIMI flow grade 0 to 1 (Tables S15 through S17).
Multimarker Risk Stratification
When candidate markers were combined into a multimarker model, 3 biomarkers emerged as significant and complementary predictors of cardiovascular death or HF through both forward and backward selection: ST2, troponin T, and MPO.
Patients with higher levels of either ST2 or MPO had more than a 2-fold higher odds of cardiovascular death or HF (adjusted OR, 2.87; 95% CI, 1.61-5.12 and adjusted OR, 2.49; 95% CI, 1.04-5.96, respectively). Similarly, patients with detectable troponin T levels in the first or second tertile had more than a 2-fold higher odds of cardiovascular death or HF (adjusted OR, 2.34; 95% CI, 1.09-5.01) and those with a troponin T concentration in the highest detectable tertile had more than a 4-fold higher odds of an event (adjusted OR, 4.13; 95% CI, 1.85-9.20; Figure 1 ). For patients in whom left ventricular ejection fraction (LVEF) had been assessed (n=515), directionally consistent findings were observed regarding the prognostic value of all 3 markers when LVEF was included in the model (Table S18) .
When an integeric multimarker risk score was created that assigned points for elevations in ST2 (1 point), troponin T (1 or 2 points), or MPO (1 point; Figure 2 ), a step-wise increase in the incidence of 30 day cardiovascular death or HF was observed for patients with higher biomarker scores (P<0.001 for trend). Furthermore, the multimarker risk score provided incremental information for risk stratification to the TIMI Risk Score for STEMI ( Figure 3 ). In particular, the multimarker risk score significantly improved the C-statistic for predicting cardiovascular death or HF as 
Discussion
In a large trial population of patients with STEMI, we evaluated the prognostic utility of 11 novel and established biomarkers. We determined that a multimarker strategy that combines Figure 2 . An integeric risk score was created using the 3 markers that were significantly associated with the odds CV death or HF including ST2, MPO, and troponin T. A step-wise increase in the incidence of 30-day CV death or HF was observed with increasing multimarker risk score. CV indicates cardiovascular; HF, heart failure; MPO, myeloperoxidase; OR, odds ratio. additive value beyond established clinical predictors and the TIMI and GRACE Risk Score for STEMI alone. These findings could therefore have implications in regards to early patient triage in the setting of acute MI. Despite marked improvements in outcomes over the past few decades, early readmission rates and mortality remain high after hospital discharge for patients hospitalized with an acute MI. 15 Therefore, it remains of key importance to continue to develop tools that may identify individuals at heightened risk of adverse outcomes who may benefit more from enhanced monitoring or potentially directed treatment strategies. In the current analysis that included up to 1258 patients with an acute MI, we found that several candidate markers-NT-proBNP, MR-proANP, ST2, troponin T, MPO, hsCRP, and PAPP-A-were individually significantly associated with the 30-day odds of cardiovascular death or HF after adjustment for clinical predictors. However, the rapid proliferation of candidate markers that appear to be useful for risk stratification has contributed to growing confusion among practitioners as to which marker may be more useful for clinical practice. Furthermore, few have been able to reliably provide incremental information for risk discrimination beyond established clinical tools. 16 In particular, there often exists a moderate-to-strong correlation between markers that reflect similar pathobiological axes of disease. As such, the relative prognostic value of any single candidate marker versus another may be unclear. By assessing multiple markers simultaneously, we were able to demonstrate that only 3 candidate markers (ST2, troponin T, and MPO) remained significantly associated with the odds of cardiovascular death or HF after adjusting for both clinical predictors and other candidate markers. Interestingly, these 3 markers reflect different pathobiological axes of disease, including myocardial stress, myocyte necrosis, and inflammation, suggesting that this type of multimarker strategy may leverage the complementary prognostic utility of each marker to further optimize risk stratification and discrimination. The current findings are supported by a multimarker analysis of 7 candidate markers in a population of patients with non-STsegment-elevation (NSTE)-ACS whereby both troponin T and MPO emerged as significant markers of long-term cardiovascular risk; however, ST2 was not evaluated. 6 In the current study of 11 candidate markers, individuals with elevated levels of ST2, troponin T, or MPO had more than a 2-fold higher odds of cardiovascular death or HF at 30 days, and those with the highest levels of troponin T had more than a 4-fold higher odds of an event after multivariable adjustment. Moreover, by combining these markers into a multimarker risk score, we were able to demonstrate a steep stepwise increase in the 30-day incidence of cardiovascular death or HF ranging from <1% for individuals with a score of 0 to 33% for individuals with a score of 4. Of note, patients with a
The prognostic utility of troponin in the setting of ACS was first established several years ago and has now been replicated across multiple trials, [17] [18] [19] [20] [21] [22] including the current study. Consistent with many previous studies, troponin T was not associated with the risk of recurrent ischemic events, but its robust prognostic value was most apparent for the odds of cardiovascular death and HF. Given that troponin concentration reflects the extent of myonecrosis, it is also a direct correlate of infarct size. 23 However, troponin release may also occur in the setting of myocardial strain 24 and may therefore help to identify patients at increased risk of cardiovascular death or HF through alternate axes of pathobiology. To that end, the prognostic value of troponin T was maintained after adjusting for surrogates of infarct size, in addition to other clinical predictors. Similarly, ST2, a soluble interleukin-1 receptor family member, is upregulated and secreted in response to mechanical stress. 25 Yet, in the current study, we observed only a weak correlation between ST2 and other markers of myocardial strain, including BNP, galectin-3, and troponin T. Similar observations have been noted in the setting of NSTE-ACS, 26 leading investigators to speculate that ST2 may not be solely a marker of myocardial strain, but also a marker of inflammation, fibrosis, and adverse myocardial remodeling.
26
MPO is an established marker of inflammation that may have proatherogenic and destabilizing effects on atheromatous plaque through a variety of proposed pathways, including low-density lipoprotein oxidation. 27 Inflammation is known to be not only a key mediator in atherogenesis and plaque rupture, but also plays a central role in myocardial wound healing after acute MI. 28 A maladaptive wound-healing response can contribute to adverse remodeling and may identify patients at increased risk of HF. Although markers of inflammation are sometimes considered to be strong correlates of infarct size, we observed only a weak correlation between MPO and troponin T concentration in the current study. Although the relationship has not always been consistent, 29 several studies have previously demonstrated an association between MPO and the risk of recurrent cardiovascular events when measured during hospitalization with ACS. 27, [30] [31] [32] The current findings therefore lend renewed support to the use of MPO as a prognostic marker after adjusting for other established risk predictors, including a wide number of biomarkers. Limitations to the current analysis warrant consideration. Samples were not available in the entire study cohort, and there remains the possibility of residual confounding despite extensive multivariable adjustment. Because there are no widely accepted cutpoints for many of the markers evaluated in the setting of acute MI, we applied thresholds on the basis of their relationship with outcomes by quartiles. Therefore, the current multimarker risk score and all applied cutpoints require further validation in additional patient populations. As well, there have been reports of preanalytical issues in regards to MPO quantification in the setting of heparin exposure. 33, 34 The samples used to assess MPO concentration in the current study were stored in EDTA plasma tubes, but the majority of patients were treated with systemic heparin as part of their acute MI management. However, one might expect that any assay interference attributed to heparin exposure would bias the results toward the null, which was not observed in the current study. For the assessment of troponin T, we used a current generation assay that is the current assay used in the United States, but future analyses may consider the use of newer high-sensitivity assays. As well, LVEF was only assessed in a subset of individuals, and therefore it was not possible to adjust for LVEF in all models; however, qualitatively consistent results were observed when this parameter was included as a covariate in a sensitivity analysis. In summary, after the simultaneous assessment of 11 novel and established biomarkers of risk in patients hospitalized with an acute MI, ST2, troponin T, and MPO emerged as significant predictors of short-term cardiovascular death or HF after adjusting for clinical predictors and other candidate markers. These findings highlight the incremental utility of combining markers that reflect complementary axes of cardiovascular disease.
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